Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
https://www.zacks.com/stock/news/2194725/biotech-stock-roundup-exel-partners-rcus-for-study-phvs-eypt-gain-on-study-data?cid=CS-ZC-FT-analyst_blog|stock_roundup-2194725
Dec 07, 2023 - Updates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week.
0
Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study
https://www.zacks.com/stock/news/2193811/exelixis-exel-collaborates-with-arcus-for-kidney-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193811
Dec 05, 2023 - Exelixis (EXEL) partners with Arcus Biosciences for a phase Ib/II study to evaluate zanzalintinib in combination with AB521 for ccRCC.
0